PSA doubling time (PSADT) and proximal PSA value predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.5075
Abstract: 5075Background: We previously reported a relationship between PSADT and MFS in BRPC post RP (Pound 1999; Freedland 2007; Antonarakis 2012). In men with PSADT read more here.
Keywords: brpc; psadt; mfs; doubling time ... See more keywords
Extended neoadjuvant chemotherapy (CT) in borderline resectable pancreatic cancer (BRPC): Updated results.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e15771
Abstract: e15771Background: Optimum therapy (Rx) for BRPC is unknown. Since 2008, we have used neoadjuvant Rx with extended course chemotherapy (CT) but not routine neoadjuvant chemoradiation (CRT). Initial ... read more here.
Keywords: chemotherapy; brpc; extended neoadjuvant; neoadjuvant chemotherapy ... See more keywords
Clinical outcomes in borderline resectable pancreatic cancer (BRPC): A single institutional analysis.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e16232
Abstract: e16232Background: Neoadjuvant therapy in BRPC serve to improve margin negative resection rate, however emerging data indicate otherwise. Aim of the study is to retrospectively investigate the clini... read more here.
Keywords: clinical outcomes; brpc; resectable pancreatic; pancreatic cancer ... See more keywords